Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

AbbVie’s Anti-Tau Antibody Enters Phase II Clinical Trials for Alzheimer’s Disease


Alzheimer's Disease

While tau is thought to stabilize neuronal structures, its abnormal accumulation has been associated with a number of neurodegenerative disorders, including Alzheimer’s disease and PSP.

Share this!

January 26, 2017 | by Sarah Hand, M.Sc.

AbbVie has commenced two Phase II clinical trials for the company’s investigational anti-tau antibody, ABBV-8E12. The drug will be evaluated in patients with early-stage Alzheimer’s disease, along with patients diagnosed with progressive supranuclear palsy (PSP).

PSP is a progressive neurodegenerative disorder which primarily affects those over the age of 60. Due to the similarity of symptoms – including balance problems and changes in movement – compared to Parkinson’s disease, PSP is often initially misdiagnosed.

Since no effective treatment exists for PSP, the US Food and Drug Administration (FDA) has granted Orphan Drug Designation and Fast Track Designation to ABBV-8E12. The European Medicines Agency (EMA) has granted orphan drug status to AbbVie’s investigational antibody for the treatment of PSP.

“We see potential in ABBV-8E12 and tau-focused approaches to progressive neurodegenerative diseases, such as early Alzheimer's disease and PSP,” said Eric Karran, vice president, Foundational Neuroscience Center, AbbVie. “The initiation of the Phase 2 clinical trial programs and the FDA's Fast Track Designation for PSP signify important steps forward in AbbVie's ongoing commitment to investigating innovative scientific approaches with the hope of bringing new treatment options to patients.”

ABBV-8E12 is a humanized antibody designed to target the tau protein. While tau is thought to stabilize neuronal structures, its abnormal accumulation has been associated with a number of neurodegenerative disorders, including Alzheimer’s disease and PSP.

Pre-clinical and phase I studies showed positive results for ABBV-8E12, supporting the further development of the anti-tau antibody in PSP and Alzheimer’s disease. Phase I results for ABBV-8E12 were presented at last year’s Clinical Trials on Alzheimer's Disease (CTAD) annual meeting.

The safety and efficacy of ABBV-8E12 will be assessed in 180 adult patients with PSP. The Phase II Alzheimer’s trial will enroll 400 patients with early-stage disease, to assess the antibody’s ability to slow disease progression.

Keywords: Tau, Alzheimer's Disease, Clinical Trials


Share this with your colleagues!

Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News

FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News

One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


Top 5 Most Impactful Tweets in Life Sciences During the Last Week


EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider

Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology

Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn

eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials

Copyright © 2016-2017 Honeycomb Worldwide Inc.